Paul Dawson

Associate Professor Paul Dawson is the Mater Research Head of Education, MRI-UQ Director of Higher Degree Research, and a Mater Foundation Principal Research Fellow. Paul leads the Neurodevelopmental Research Group at Mater, which is focussed on cerebral palsy in preterm infants, non-syndromic intellectual disability and autism.

Paul’s research group collaborates very closely with neonatologists, maternal fetal medicine specialists, obstetricians, bioinformaticians and biochemical pathologists at Mater to investigate clinical, biochemical and genetic markers that predict adverse neurodevelopmental outcomes. In particular, his research is focussed on the role of nutrient sulphate in brain development. Paul through his work has brought many collaborative groups together. Some of his notable collaborations are with the Queensland Brain Institute (QBI), Royal Brisbane and Women’s Hospital (RBWH), UQ Centre for Clinical Research (UQCCR), the University of Sydney and the Cerebral Palsy Alliance.

With over 80 research publications, Paul notes a career highlight as being one of the key investigators, and Autism Biobank member, in the Autism Cooperative Research Centre (CRC) which was awarded $31 million from the Australian government.

Paul is heavily involved in national and international peer review and is a strong advocate for health and medical research with executive roles (Past-President 2012, Chair Advisory Committee) for the Australian Society for Medical Research (ASMR).

‘My career in medical research happened for many reasons, including my interest and passion for understanding the genetics of disorders that impact on people’s health and well-being. In my early days, I was fortunate to work with a group of like-minded biomedical and clinician scientists which kicked off many discoveries in neurodevelopment, as well as the opportunity to develop and investigate pre-clinical models with the aim of implementing research outcomes to improve healthcare. Working at Mater provides a fantastic opportunity to investigate new approaches for reducing the risk of adverse neurodevelopmental outcomes in preterm infants. I look forward to the coming years when the benefits of our Mater-led research will be realised and proven around the globe. It’s a privilege to contribute to Australian health and medical research.’